XOMA Royalty Corp 4

BVF Partners L.P., its affiliated funds, and Mark N. Lampert disposed of their XOMA Royalty Corp common stock in a July 14, 2026 cash merger at $39.00 per share plus contingent value rights.

On July 14, 2026, the BVF complex of funds and affiliates, including Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS LP, BVF Partners L.P., BVF Inc., and Mark N. Lampert, reported the disposition of their entire XOMA Royalty Corp common stock position in connection with the closing of a cash merger under which Ligand Pharmaceuticals Incorporated acquired all outstanding XOMA shares. The Form 4 shows four separate line items of common stock, representing positions held directly by different BVF entities and managed accounts, all reported as dispositions coded “U” (transaction pursuant to a merger) at an implied price of $39.00 per share, with no shares remaining after the transaction in the directly held accounts and a residual indirect holding footnoted as having been exchanged for the same merger consideration. The reporting persons collectively were members of a Section 13(d) group owning more than 10% of XOMA’s outstanding shares prior to the merger and received $39.00 in cash plus contingent value rights for each share of XOMA common stock tendered into the transaction.

Filing Facts

CIK

791908

Ticker

XOMA

Form

4

Source Type

fda

Accession

0000921895-26-001823

Alert Tier

6